Nasopharyngeal carcinoma secondary prevention: Difference between revisions
YazanDaaboul (talk | contribs) |
m Bot: Removing from Primary care |
||
(5 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
{{Nasopharyngeal carcinoma}} | {{Nasopharyngeal carcinoma}} | ||
{{CMG}} {{AE}}{{Faizan}} | {{CMG}} {{AE}}{{Homa}}{{Faizan}} | ||
==Overview== | ==Overview== | ||
Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively. | Secondary prevention measures of nasopharyneal cancer include routine [[physical examination]] and [[imaging]] at scheduled intervals after treatment. [[Dental]] [[Screening (medicine)|screening]] and [[Screening (medicine)|screening]] for [[Thyroid cancer|thyroid cancers]] are recommended among [[patients]] who had received [[radiation therapy]] to the [[oral cavity]] and [[cervical]] region, respectively. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for nasopharyngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref> | [[Patients]] treated for nasopharyngeal carcinoma should follow-up for [[secondary prevention]]. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref><ref name="ChanGregoire2012">{{cite journal|last1=Chan|first1=A. T. C.|last2=Gregoire|first2=V.|last3=Lefebvre|first3=J.- L.|last4=Licitra|first4=L.|last5=Hui|first5=E. P.|last6=Leung|first6=S. F.|last7=Felip|first7=E.|title=Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up|journal=Annals of Oncology|volume=23|issue=suppl 7|year=2012|pages=vii83–vii85|issn=0923-7534|doi=10.1093/annonc/mds266}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Follow up}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Follow up}} | ||
Line 26: | Line 26: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
: | :Nasoendoscopy | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Immediately following radiation therapy | *Immediately following [[radiation therapy]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
Line 36: | Line 36: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Scans are performed at routine intervals as follows: | Scans are performed at routine intervals as follows: | ||
*Baseline scanning is performed at 3-6 months after treatment, further scans are scheduled based on finding of physical exam and symptoms experienced by the patient | *Baseline scanning is performed at 3-6 months after treatment, further scans are scheduled based on finding of [[physical exam]] and [[symptoms]] experienced by the [[patient]] | ||
*Scanning for asymptomatic patients is not recommended | *Scanning for [[asymptomatic]] [[patients]] is not recommended | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
:Thyroid hormone testing | :Thyroid hormone testing | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Thyroid stimulating hormone testing every 12 months if the neck was exposed to radiation | *[[Thyroid stimulating hormone]] testing every 12 months if the [[neck]] was exposed to [[radiation]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
:Dental screening | :Dental screening | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Only recommended if oral cavity was exposed to radiation | *Only recommended if [[oral cavity]] was exposed to [[radiation]] | ||
|- | |- | ||
|} | |} | ||
==References== | ==References== | ||
Line 58: | Line 57: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Oncology]] | |||
[[Category:Otolaryngology]] |
Latest revision as of 22:54, 29 July 2020
Nasopharyngeal carcinoma Microchapters |
Differentiating Nasopharyngeal carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Nasopharyngeal carcinoma secondary prevention On the Web |
American Roentgen Ray Society Images of Nasopharyngeal carcinoma secondary prevention |
Risk calculators and risk factors for Nasopharyngeal carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively.
Secondary Prevention
Follow up after treatment
Patients treated for nasopharyngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1][2]
Follow up | Description |
---|---|
|
|
|
|
|
Scans are performed at routine intervals as follows:
|
|
|
|
|
References
- ↑ Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.
- ↑ Chan, A. T. C.; Gregoire, V.; Lefebvre, J.- L.; Licitra, L.; Hui, E. P.; Leung, S. F.; Felip, E. (2012). "Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (suppl 7): vii83–vii85. doi:10.1093/annonc/mds266. ISSN 0923-7534.